NEW HAVEN, Conn., July 27, 2026
Biohaven Ltd. and Yale University have secured a significant legal victory after a federal jury in the U.S. District Court for the District of Delaware found that Avilar Therapeutics and RA Capital Management GP, LLC willfully and maliciously misappropriated trade secrets related to Yale’s MODA targeted protein degradation platform. The jury also determined that RA Capital breached a 2019 confidentiality agreement with Yale, resulting in a combined $4 million damages award. The verdict includes $2 million awarded to Yale for breach of contract and $1 million each to Yale and Biohaven for trade secret misappropriation. The ruling represents a major development in the protection of biopharmaceutical intellectual property, reinforcing the importance of confidentiality agreements and safeguarding proprietary technologies that support the discovery and development of innovative medicines. The case also highlights the growing strategic value of targeted protein degradation platforms, which have emerged as one of the biotechnology industry’s most promising approaches for developing next-generation therapeutics across multiple disease areas.
Federal Jury Upholds Trade Secret Protection for MODA Platform
The legal dispute centered on Yale’s MODA extracellular targeted protein degradation platform, an innovative technology developed by Dr. David Spiegel, a professor at Yale University. According to court findings, RA Capital entered into a confidentiality agreement with Yale in 2019 while evaluating a potential investment and partnership involving the technology. During negotiations, Yale shared detailed confidential scientific information regarding the MODA platform, which is designed to selectively bind and eliminate disease-causing extracellular proteins. Biohaven and Yale argued that after partnership discussions concluded without an agreement, RA Capital and Avilar Therapeutics used confidential information obtained during those discussions to establish and advance a competing drug development program. After reviewing evidence presented during the trial, the federal jury concluded that the defendants had willfully and maliciously misappropriated Yale’s trade secrets, while also determining that RA Capital breached its contractual confidentiality obligations, reinforcing the legal protections surrounding proprietary biotechnology innovations.
Verdict Reinforces Importance of Intellectual Property in Biopharma
The jury’s decision represents an important reminder of the critical role intellectual property protection plays throughout the biopharmaceutical innovation ecosystem. Universities, biotechnology companies, venture capital firms, and pharmaceutical partners frequently collaborate to translate academic discoveries into commercial therapies, making trust and contractual compliance essential for successful innovation. Biohaven stated that the verdict validates its longstanding position that confidential scientific information was improperly used to advance competing research programs. Yale emphasized that groundbreaking discoveries developed through years of scientific research depend on strong legal protections that enable productive partnerships between academia and industry. The ruling reinforces the importance of maintaining confidentiality throughout technology evaluation and licensing negotiations while helping preserve incentives for continued investment in drug discovery, translational medicine, and therapeutic platform development.
Advertisement
MODA Platform Supports Next-Generation Drug Discovery Innovation
The MODA targeted protein degradation platform, licensed by Biohaven from Yale, represents a promising approach for developing therapies capable of selectively eliminating disease-causing extracellular proteins, expanding opportunities beyond traditional intracellular protein degradation technologies. As biotechnology companies increasingly invest in precision medicine, protein degradation, and novel therapeutic platforms, protecting proprietary scientific discoveries has become increasingly important to maintaining innovation and encouraging commercial collaboration. The federal jury’s decision strengthens confidence in the legal framework supporting biotechnology licensing agreements while reinforcing the value of protecting breakthrough research developed through academic institutions. For Biohaven, the outcome supports continued advancement of its growing pipeline spanning neuroscience, immunology, and other therapeutic areas, while emphasizing the company’s commitment to responsible innovation, scientific collaboration, and the commercialization of transformative medicines for patients with debilitating diseases.
Source: Biohaven press release
